PACK-CXL For All
The concept of using photoactivated chromophores for corneal cross-linking (PACK-CXL) as a weapon against infectious keratitis is compelling
Prof. Farhad Hafezi
May 15, 2014
The concept of using photoactivated chromophores for corneal cross-linking (PACK-CXL) as a weapon against infectious keratitis is compelling
Infectious keratitis is a leading cause of global blindness, with an estimated 5 million new cases occurring every year in developing countries
EMAGine SA, a spin-off company from the University of Geneva and co-founded by Nikki and Farhad Hafezi, is elected amongst the best start-ups in Switzerland in 2014
An optimized treatment protocol, a miniaturized device that mounts on a slit lamp and a new photosensitizing agent may allow for a faster and more effective application of cross-linking for infectious keratitis in the near future.
Read here (Article in Portuguese).
Read here (Article in Slovenian).
Keratoconus is extremely frequent in Down Syndrome
Editorial on how to translate research into clinical applications in the field of ophthalmology
First symposium on translational research in ophthalmology